Claus A. Andersson - 09 Nov 2021 Form 4 Insider Report for IO Biotech, Inc. (IOBT)

Reporting relationship: Director
Issuer ticker: IOBT
Reported as of: 09 Nov 2021
Net transaction value: +$1,050,000
SEC form: 4
Accepted by SEC: 12 Nov 2021, 15:16:01 UTC
Prior SEC filing: 04 Nov 2021
Source filing: View source filing
Reporting owner signature: /s/ Brian Burkavage, Attorney-in-Fact for Claus Andersson

Key filing fact

Claus A. Andersson filed Form 4 for IO Biotech, Inc. (IOBT) on 12 Nov 2021.

Key facts

This page summarizes Claus A. Andersson's Form 4 filing for IO Biotech, Inc. (IOBT).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 12 Nov 2021, 15:16.

Change

Previous filing in this sequence was filed on 04 Nov 2021.
Current net transaction value: +$1,050,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IOBT transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +1,361,660
Change %
Price
Shares after: 1,361,660
Date: 09 Nov 2021
Ownership: See footnote
Footnotes: F1, F3

IOBT transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +354,830
Change %: +26%
Price
Shares after: 1,716,490
Date: 09 Nov 2021
Ownership: See footnote
Footnotes: F2, F3

IOBT transaction

Common Stock

Purchase

Transaction value: $1,050,000
Shares: +75,000
Change %: +4.4%
Price: $14.00^*
Shares after: 1,791,490
Date: 09 Nov 2021
Ownership: See footnote
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IOBT transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -147,881
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 09 Nov 2021
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 1,361,660
Exercise price
Footnotes: F1, F3

IOBT transaction Derivative

Series C Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -28,225
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 09 Nov 2021
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 354,830
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date.

Footnote F2

Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date.

Footnote F3

Sunstone Life Science Ventures Fund III K/S ("Sunstone Fund III"). Sunstone LSV General Partner III ApS ("Sunstone LSV GP III") is the general partner of Sunstone Fund III and has voting and dispositive power over all of the shares of held by Sunstone Fund III. The reporting person is a General Partner of Sunstone Life Science Ventures A/S and a member of the executive board of Sunstone LSV GP III, and shares voting and dispositive power with respect to the shares held by Sunstone Fund III. The reporting person disclaims beneficial ownership of the shares held directly by Sunstone Fund III except to the extent of his pecuniary interest therein.